Opendata, web and dolomites

Respiratory-ImmunoDx SIGNED

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Respiratory-ImmunoDx project word cloud

Explore the words cloud of the Respiratory-ImmunoDx project. It provides you a very rough idea of what is the project "Respiratory-ImmunoDx" about.

immunodx    comprising    drop    biomarker    versus    ivd    innovative    1000    accelerated    overuse    slowing    signature    host    public    worldwide    significantly    managed    point    insufficient    blood    aligned    million    burden    validated    clinically    disease    goals    initially    antibiotic    emergence    ce    ageing    trail    instrument    give    death    prohibit    immunoxperttm    older    clearance    lrti    adoption    hours    approved    infections    accurate    viral    profoundly    health    complications    bacteria    1100    adverse    diagnosis    light    quality    prospective    infection    enrolling    outpatient    annually    resistant    guiding    device    tools    respiratory    tract    incidents    life    3rd    market    immunoxpert    outperforming    distinguished    globally    actionable    protein    lab    tests    clinical    lrtis    risk    gt    diagnostic    trade    strategy    validate    population    treatment    bacterial    pon    accurately    performed    billion    adult    memed    sme    lower    reducing    measured    adults    validating    physicians    mortality    impactful    patients    regulatory    pioneering    setting    obtain    underuse    subpopulation    46   

Project "Respiratory-ImmunoDx" data sheet

The following table provides information about the project.

Coordinator
MEMED DIAGNOSTICS LTD 

Organization address
address: NAHUM HETH STREET 5
city: TIRAT CARMEL
postcode: 39120
website: www.me-med.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.me-med.com/html5/
 Total cost 2˙935˙000 €
 EC max contribution 2˙935˙000 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEMED DIAGNOSTICS LTD IL (TIRAT CARMEL) coordinator 2˙935˙000.00

Map

 Project objective

Lower respiratory tract infection (LRTI) is the 3rd leading cause of death worldwide. In the EU 30 million incidents occur annually, with associated costs of €46 billion. Older adults are at higher risk of developing LRTI, and therefore, in light of Europe's ageing population, the disease burden will increase. Since most adult LRTIs are managed in the outpatient setting, innovative diagnostic tools for guiding treatment at the point-of-need (PON), would be impactful. MeMed identified a host-biomarker signature comprising a novel viral induced protein called TRAIL. Based on this signature, MeMed developed a test called ImmunoXpertTM (CE-IVD approved). In a prospective study with >1000 patients, ImmunoXpert™ accurately distinguished viral versus bacterial infections, significantly outperforming traditional tests. Two factors prohibit wide adoption of ImmunoXpert for managing LRTI adult patients: i) insufficient clinical evidence validating the signature in this subpopulation and ii) ImmunoXpert™ is performed in a lab and requires 2 hours. To address this we propose:

• To clinically validate the biomarker signature for accurate diagnosis of viral versus bacterial LRTI, in a prospective study enrolling 1100 adult EU patients at the PON

• To develop, validate and obtain EU regulatory clearance for a new PON device (to be called ImmunoDx™) that rapidly measures the signature from a drop of blood

These objectives are highly aligned with the SME instrument goals and MeMed’s strategy. They will allow a pioneering test to achieve accelerated market adoption, initially in Europe and then globally. The validated signature, measured using ImmunoDx™, will give physicians, accurate and actionable information at the PON. This test has potential to profoundly impact patients' quality of life by reducing adverse effects due to antibiotic overuse; reducing complications and mortality due to underuse; and slowing the emergence of antibiotic resistant bacteria, a major public health

 Deliverables

List of deliverables.
A dedicated website for OBSERVER and ImmunoDxâ„¢ Websites, patent fillings, videos etc. 2019-05-31 17:19:04
Presenting at infectious disease conference Websites, patent fillings, videos etc. 2019-05-31 17:19:02

Take a look to the deliverables list in detail:  detailed list of Respiratory-ImmunoDx deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPIRATORY-IMMUNODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESPIRATORY-IMMUNODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

PNEUMOSIP (2015)

PNEUMOSIP

Read More  

Respiratory-ImmunoDx (2015)

Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections (LRTI) in adults at the point-of-need

Read More  

OncoMasTR (2016)

OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer

Read More